| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 23.9MM | -1% |
| Gross Profit | 16.6MM | - |
| Cost Of Revenue | 7.3MM | -41% |
| Operating Income | -33.5MM | -25% |
| Operating Expenses | 50.1MM | - |
| Net Income | -42.1MM | -8% |
| R&D | 29.9MM | +24% |
| G&A | 17.3MM | -18% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript March 4, 2024 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2. NKTR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for […]
Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.
Q4 2023 Nektar Therapeutics Earnings Call
Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Financial Highlights Reflect Cost Management Amidst R&D Progress
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023.